Analysis of Competing Risks of Causes of Death in Cancer Patients from Golestan, Iran over Twelve Years (2004-2016).
Aged
Cause of Death
Cross-Sectional Studies
Female
Humans
Incidence
Iran
/ epidemiology
Logistic Models
Male
Middle Aged
Myocardial Ischemia
/ mortality
Neoplasms
/ epidemiology
Registries
/ statistics & numerical data
Risk
Rural Population
/ statistics & numerical data
Survival Rate
Time Factors
Urban Population
/ statistics & numerical data
Cause of Death
Golestan
Iran
cancer
mortality
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
received:
16
02
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
5
2
2022
Statut:
epublish
Résumé
Cancer-related causes of death (cancer CoD) are the main etiologies of death in cancer patients. Recent increase in survival rates of cancer patients resulted in higher risk of dying from causes other than cancer, called competing causes of death (competing CoD). We aim to characterize competing CoD among cancer patients in Golestan province, Northern Iran. Data on cancer incidence was obtained from the Golestan population-based cancer registry (GPCR) dataset. Data on causes of death was obtained from the Golestan death registry (GDR) dataset. Using a linkage method between the GPCR and GDR dataset, we prepared the study dataset including data on vital status and causes of death in our cancer patients. The proportions of cancer CoD and competing CoD were calculated. Multivariate logistic regression analysis was considered to assess the relationship between competing CoD and other variables. Overall, 4,184 cancer patients died in the study population, including 2,488 men (59.9%). Cause of death in 3,455 cases was cancer and 729 cases (17.4%) died due to competing CoD. Ischemic heart disease (40.7%) was the most common competing CoD in our population. Higher survival rate was the strongest variable related to the competing CoD (adjusted OR=1.91; 95%CI: 1.61-2.26). Residence area, age group and year of death were other indicators of competing CoD in our population. Our results suggest high rates of competing CoD in our cancer patients. Competing CoD should be mentioned in cancer control planning both in clinical practice as well as in public health policy making.<br />.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer-related causes of death (cancer CoD) are the main etiologies of death in cancer patients. Recent increase in survival rates of cancer patients resulted in higher risk of dying from causes other than cancer, called competing causes of death (competing CoD). We aim to characterize competing CoD among cancer patients in Golestan province, Northern Iran.
METHODS
METHODS
Data on cancer incidence was obtained from the Golestan population-based cancer registry (GPCR) dataset. Data on causes of death was obtained from the Golestan death registry (GDR) dataset. Using a linkage method between the GPCR and GDR dataset, we prepared the study dataset including data on vital status and causes of death in our cancer patients. The proportions of cancer CoD and competing CoD were calculated. Multivariate logistic regression analysis was considered to assess the relationship between competing CoD and other variables.
RESULTS
RESULTS
Overall, 4,184 cancer patients died in the study population, including 2,488 men (59.9%). Cause of death in 3,455 cases was cancer and 729 cases (17.4%) died due to competing CoD. Ischemic heart disease (40.7%) was the most common competing CoD in our population. Higher survival rate was the strongest variable related to the competing CoD (adjusted OR=1.91; 95%CI: 1.61-2.26). Residence area, age group and year of death were other indicators of competing CoD in our population.
CONCLUSION
CONCLUSIONS
Our results suggest high rates of competing CoD in our cancer patients. Competing CoD should be mentioned in cancer control planning both in clinical practice as well as in public health policy making.<br />.
Identifiants
pubmed: 34710989
doi: 10.31557/APJCP.2021.22.10.3137
pmc: PMC8858227
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3137-3142Références
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
Adv J Emerg Med. 2019 Jul 11;4(1):e3
pubmed: 31938772
J Chronic Dis. 1984;37(12):903-8
pubmed: 6526929
N Engl J Med. 2018 Dec 20;379(25):2438-2450
pubmed: 30575480
Expert Rev Anticancer Ther. 2017 Sep;17(9):873-878
pubmed: 28618843
Cancer Epidemiol. 2018 Feb;52:128-133
pubmed: 29306787
J Cancer Surviv. 2019 Oct;13(5):739-748
pubmed: 31440947
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):992-997
pubmed: 28600296
Arch Iran Med. 2012 Apr;15(4):196-200
pubmed: 22424034
Med Care. 2010 Jun;48(6 Suppl):S96-105
pubmed: 20473207
BJOG. 2016 Jan;123(2):293-8
pubmed: 26841334
Ann Oncol. 2017 Feb 1;28(2):400-407
pubmed: 27831506
Curr Opin Clin Nutr Metab Care. 2011 Jan;14(1):28-34
pubmed: 21102320
Cancer Epidemiol. 2011 Apr;35(2):126-31
pubmed: 20952269
Cancer Med. 2020 Mar;9(5):1741-1752
pubmed: 31960609
Gynecol Oncol. 2012 Aug;126(2):176-9
pubmed: 22507532
Nat Commun. 2020 Apr 24;11(1):2011
pubmed: 32332714
Science. 1972 Feb 25;175(4024):846-53
pubmed: 5008604
Cancer. 2014 Aug 1;120(15):2334-42
pubmed: 24752471
Eur J Cancer Care (Engl). 2017 Jan;26(1):
pubmed: 27430738
Arch Iran Med. 2019 Jan 01;22(1):1-6
pubmed: 30821154
Breast Cancer Res. 2011 Jun 20;13(3):R64
pubmed: 21689398
Cancer Epidemiol. 2020 Aug;67:101728
pubmed: 32554298
CA Cancer J Clin. 2016 Jul;66(4):309-25
pubmed: 26919165
Gynecol Oncol. 2015 Aug;138(2):421-8
pubmed: 26050923
Ann Thorac Med. 2018 Apr-Jun;13(2):76-81
pubmed: 29675057
Int J Cancer. 2017 Feb 1;140(3):555-564
pubmed: 27741565
JAMA Cardiol. 2017 Jan 1;2(1):88-93
pubmed: 27732702
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Br J Cancer. 1973 Sep;28(3):197-214
pubmed: 4743904
J Adv Res. 2019 Jul 16;20:153-159
pubmed: 31467707
Oral Oncol. 2017 Feb;65:8-15
pubmed: 28109473
MMWR Surveill Summ. 2017 Jan 13;66(2):1-7
pubmed: 28081057